The burden of diabetes and hyperlipidemia in treated HIV infection and approaches for cardiometabolic care

Curr HIV/AIDS Rep. 2012 Sep;9(3):206-17. doi: 10.1007/s11904-012-0124-x.


Treatment of HIV infection with highly active antiretroviral therapy (HAART) confers survival and quality of life benefits. However, these significant benefits are at the cost of metabolic complications with associated increased risk of type 2 diabetes and cardiovascular disease. These chronic diseases add complexity to the standards of care in HIV infection and much remains unknown about the natural histories of diabetes and hyperlipidemia in this setting. This review examines recent research findings in diabetes and hyperlipidemia in HIV infection, juxtaposed on our prior understanding of these diseases. It also reviews the current evidence base and clinical guidelines for diabetes and lipid management and cardiometabolic prevention in HIV-infected HAART recipients.

Publication types

  • Review

MeSH terms

  • Acquired Immunodeficiency Syndrome / blood
  • Acquired Immunodeficiency Syndrome / drug therapy
  • Acquired Immunodeficiency Syndrome / epidemiology*
  • Age Distribution
  • Antiretroviral Therapy, Highly Active
  • Cost of Illness*
  • Diabetes Mellitus / blood
  • Diabetes Mellitus / drug therapy
  • Diabetes Mellitus / epidemiology*
  • Guidelines as Topic
  • Humans
  • Hyperlipidemias / blood
  • Hyperlipidemias / drug therapy
  • Hyperlipidemias / epidemiology*
  • New South Wales / epidemiology
  • Obesity / blood
  • Obesity / drug therapy
  • Obesity / epidemiology*
  • Prevalence
  • Quality of Life
  • Risk Factors
  • Sex Distribution